SSA
ARCT icon

Schonfeld Strategic Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-230,500
Closed -$3.63M – 2931
2022
Q2 		$3.63M Buy
+230,500
New +$4.52M 0.04% 557
2022
Q1 		– Sell
-275,000
Closed -$10.2M – 2572
2021
Q4 		$10.2M Buy
275,000
+225,000
+450% +$9.17M 0.09% 282
2021
Q3 		$2.39M Buy
+50,000
New +$2.24M 0.02% 654
2020
Q4 		– Sell
-50,000
Closed -$2.15M – 1556
2020
Q3 		$2.15M Buy
+50,000
New +$2.48M 0.04% 494

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's ARCT Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 69,755 shares — an estimated $428K sold.

Schonfeld Strategic Advisors first reported a position in ARCT in Q2 2020 and held it in 20 quarters. The position peaked at $14.4M in Q4 2024. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 69,755 Arcturus Therapeutics shares in Q1 2026, an estimated $428K.
  • Schonfeld Strategic Advisors first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 20 quarters.
  • Schonfeld Strategic Advisors's Arcturus Therapeutics position peaked at $14.4M in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.